Skip to main navigation
  • Back to SpringWorksTx.com
  • Investors & Media
  • Contact Us
  • Linkedin
  • Twitter
SpringWorks
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Corporate Governance
  • Financial Information
    • SEC Filings
    • Annual Reports
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Investor Resources
    • Investor FAQs
    • Investor Contacts
    • Email Alerts
  • Investors + Media
  • Medical Professionals
  • Contact Us
  • Linkedin
  • Twitter

Investor Relations

The full potential of targeted oncology is waiting to be unlocked.

Corporate Profile

SpringWorks Therapeutics is a commercial-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines to help patients suffering from devastating cancers live longer, better lives.
View Corporate Presentation

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

08 Dec 2023
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
05 Dec 2023
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
04 Dec 2023
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
29 Nov 2023
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
View All

Upcoming Events

There are no upcoming events scheduled at this time.
View All Events

Featured Reports & Presentations

OGSIVEO™ FDA Approval Call Presentation 3.8 MB
ReNeu Topline Results Presentation 2.2 MB

Featured Pages

Blue background
Corporate Governance
Corporate Governance
Teal Background
Financial Information
Financial Information
Blue background
Stock Information
Stock Information
Teal Background
Investor Resources
Investor Resources

Springworks - Toolkits

  • Print Page
  • Email Alerts
  • RSS Feeds
  • Investor Contacts

Springworks Logo

Social Links

  • linkedin
  • twitter
Footer 1
  • Who We Are
    • Leadership & Board
    • Mission & Values
    • DE&I
    • Partners & Collaborators
  • Focus Areas
    • Rare Oncology
    • BCMA Combinations in Multiple Myeloma
    • Biomarker-Defined Metastatic Solid Tumors
Footer 2
  • Pipeline
    • Nirogacestat
    • Mirdametinib
    • Clinical Trials
    • Investigator-Initiated Research
    • Key Scientific Presentations and Publications
  • Careers
    • View Opportunities
Footer 3
  • Patients
    • Desmoid Tumors
    • NF1-PN
    • Expanded Access
  • Contact
Footer 4
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Investor Resources

© 2023 SpringWorks Therapeutics. All rights reserved.

Copyright Links

  • Privacy Policy
  • Terms of Use
  • Cookie Policy